Ask Warren

JONBUR Research · Update note

Hanwha Life Insurance · 088350 · Insurance

Hanwha Life Falls 7% on Q3 Loss Forecast and Halt in Key Product Sales

Why this report

Written after:

Hanwha Life shares fell about 7% on 2026-10-21 after news reports of an expected third-quarter loss and a halt in sales of a key product. The reports challenge the earnings-improvement part of our earlier picture, but no company filing with the figures was provided to us.

Written Oct 21, 2026 · Data as of Oct 20, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

What happened

A Chosun Biz article on 2026-10-21 reported that Hanwha Life fell 7% on a Q3 loss forecast and a halt in sales of a key product. Seoul Economic Daily said the drop also reflected uncertainty over the dividend.

On 2026-10-20, Maeil Business Newspaper and Yonhap reported that iM Securities lowered its target price and cited interest rate and exchange rate effects that worsen investment losses. Etoday put iM Securities' new target at ₩5,400 and said it expects a Q3 loss. These are broker views, not company figures.

The company's own Q3 result, the size of any loss, and the product affected are not in the data we have. No filing excerpts were provided for this event. The shares closed at ₩4,630 on 2026-10-20, down 21.0% over one month and 45.8% above a year earlier. That close predates the 7% fall reported for 2026-10-21. Two filings on 2026-10-20 (a major management matter and a related-party transaction) have no details available.

What it changes for the thesis

Our 2026-10-13 initiation described low multiples and rising trailing profit, but said the quality and sustainability of earnings were unclear. It also flagged negative free cash flow of -₩599.3B, liabilities at 866.8% of equity, and a rights offering whose terms were unknown.

A Q3 loss, if confirmed, would cut against the rising-profit part of that picture. The reported dividend uncertainty matters too, since the yield is shown as 0.0%. The reports also suggest that investment results are sensitive to interest rates and exchange rates. This fits the earlier concern about earnings quality, though we cannot verify the size of the effect.

The trailing figures are unchanged: net income of ₩1,062.1B to H1 2026 and ROE of 7.6%. They do not yet include Q3.

What it changes for the valuation

The previous report had no model fair value. The model now gives a model estimate based on the assumptions shown of ₩8,777 per share in the base case, with a bear case of ₩3,451 and a bull case of ₩15,698, using a 9.7% rate and trailing figures to H1 2026. The range is very wide, which shows how sensitive the estimate is to its assumptions.

The model does not include the expected Q3 loss. If the loss is confirmed, the inputs could change. Against the ₩4,630 close on 2026-10-20, the price sits between the bear and base cases. Current multiples on that close are a P/E of 3.8 and a P/B of 0.2, versus 4.2 and 0.3 in the previous report. These rest on trailing profit that may not hold.

Closing view

The news raises doubts about near-term earnings and the dividend, which the earlier report treated as open questions. Against that, trailing profit is higher than in 2025, multiples are low, and the model range is wide, with the share price inside it. Key facts are still missing: the company's own Q3 figures, the halted product and its importance, and the terms of the rights offering. Until those are available, the evidence is mixed and the conclusion is unsettled. This note is not a recommendation.

Model estimate of fair value

Bear
₩3,451
-15%
Base
₩8,777
+117%
Bull
₩15,698
+288%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the P/B vs ROE (excess return) model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 9.7%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

Report history

  1. Oct 21, 2026Update noteNewsHanwha Life Falls 7% on Q3 Loss Forecast and Halt in Key Product Sales
  2. Oct 13, 2026InitiationHanwha Life: Low Book Multiples, Rising Profit, a Recent Pullback and a New Rights Offering Filing

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information